Prince A M, Jacobs R F
J Ark Med Soc. 2001 Oct;98(4):115-8.
The incidence of serious RSV illness in premature infants and in infants with CLD can be reduced. Prophylaxis in infants with CHD and cystic fibrosis seem prudent as well, and clinical trials are currently under way to evaluate the use of Synagis in these high-risk groups. Synagis is preferred for most high-risk children because of its ease of administration, safety and effectiveness. The dose for Synagis is 15 mg/kg i.m. monthly during RSV season.
早产儿和患有慢性肺病的婴儿发生严重呼吸道合胞病毒（RSV）疾病的几率可以降低。对患有先天性心脏病（CHD）和囊性纤维化的婴儿进行预防似乎也是合理的，目前正在进行临床试验以评估在这些高危人群中使用帕利珠单抗（Synagis）的情况。由于其给药方便、安全性和有效性，帕利珠单抗在大多数高危儿童中是首选。帕利珠单抗的剂量为在RSV季节每月15mg/kg，肌肉注射。
Zotero 插件